You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Sensor-Enabled Elder Social Support Platform

    SBC: KINNEXXUS, INC.            Topic: NIA

    DESCRIPTION (provided by applicant): As elders age, they need increasing amounts of adaptive assistance and care from their caregivers- people who are often busy or remote. With the baby boomer generation preparing to retire, the sheer number of people who will need support will far outstrip the nation's ability to provide professional caregivers. Furthermore, the nation will not be able to afford ...

    STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
  2. Online Psychosocial Assessment Instruments Technology Transfer

    SBC: KINNEXXUS, INC.            Topic: NIA

    DESCRIPTION (provided by applicant): As elders age, they need increasing amounts of adaptive assistance and care from their caregivers- people who are often busy or remote. With the baby boomer generation preparing to retire, the sheer number of people who will need support will far outstrip the nation's ability to provide professional caregivers. Furthermore, the nation will not be able to afford ...

    STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
  3. Allergen???Fc-gamma1 proteins to treat food allergy

    SBC: TUNITAS THERAPEUTICS, INC.            Topic: NIAID

    DESCRIPTION (provided by applicant): The goal of this proposal is to develop and commercialize a novel approach for allergen specific immunotherapy as treatment for severe food allergy. Food allergy affects about 3.5% of the US population and 6% to 8% of young children. It is clearly on the rise. Peanut allergy, which affects around 1% of the population, is among the most severe food allergies, r ...

    STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
  4. Advancing clemizole for hepatitis C: towards a pre-IND package

    SBC: EIGER GROUP INTERNATIONAL, INC.            Topic: NIAID

    DESCRIPTION (provided by applicant): Over 150 million people worldwide are infected with the hepatitis C virus (HCV), which is an important cause of chronic liver disease. Current therapies are inadequate. Our long-term objective is to bring a new class of anti-HCV drugs to the clinic. We recently discovered and genetically validated a new target within the HCV non-structural protein NS4B, consist ...

    STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
  5. Identification of novel therapeutics for tuberculosis combining cheminformatics,

    SBC: COLLABORATIVE DRUG DISCOVERY, INC.            Topic: NIAID

    DESCRIPTION (provided by applicant): This Small Business Technology Transfer Phase I project entitled Identification of novel therapeutics for tuberculosis combining cheminformatics, diverse databases and logic-based pathway analysis describes the development of software that will facilitate new drug discovery efforts for Mycobacterium tuberculosis (TB). The amount of research performed on TB co ...

    STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
  6. Evaluation of Staphylococcus aureus agr-based Quorum Sensing as Vaccine Candidate

    SBC: SORRENTO THERAPEUTICS, INC.            Topic: NIAID

    DESCRIPTION (provided by applicant): In this proposal we lay out a comprehensive research plan to evaluate our passive vaccination strategies targeting Staphylococcus aureus/MRSA to prevent or treat infections associated with S. aureus/MRSA. With the emergence of highly antibiotic-resistant bacterial strains, most notably MRSA, new approaches for combating bacterial infections are desperately nee ...

    STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
  7. Plant-Derived Estrogens and Cell Proliferation

    SBC: BIONOVO, INC.            Topic: NCCAM

    DESCRIPTION (provided by applicant): Menopause is associated with about a 10-15 pound weight gain and a redistribution of fat to the abdomen. The increase in abdominal fat, also known as visceral fat is known to produce cytokines that cause inflammation which can lead to the metabolic syndrome. The metabolic syndrome represents a major public health burden because it increases the risk of cardiova ...

    STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
  8. Development of an Electromyographically Controlled Electrolarynx Voice Prosthesis

    SBC: GRIFFIN LABORATORIES, INC.            Topic: NIDCD

    DESCRIPTION (provided by applicant): The most common artificial voice source for post-laryngectomy speech rehabilitation is the hand-held buzzer or electrolarynx (EL). This device is relatively easy to use and enables most laryngectomees to verbally communicate, but with reduced intelligibility and markedly degraded naturalness. In addition, EL speech is often described as robotic and monotone, at ...

    STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
  9. Islet Protection from Hypoxia Posttransplant

    SBC: BIOINVENTIONS, LLC            Topic: NIDDK

    DESCRIPTION (provided by applicant): Islet transplantation (ITx), especially with the emerging potential of xenotransplantation, holds significant promise for the treatment of type 1 diabetes (T1D). There are, however, major challenges that remain prior to its larger scale, cost-effective application. Hypoxia is a leading stress post-transplantation and is estimated to cause the death of approxima ...

    STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
  10. ApoFasL as a novel treatment for Type 1 Diabetes in Nonhuman Primates

    SBC: APOIMMUNE, INC            Topic: NIDDK

    DESCRIPTION (provided by applicant): Pancreatic islet transplantation is a viable approach for the treatment of type 1 diabetes (T1D). However, this therapeutic approach suffers from graft rejection. Dr. Shirwan, founder of ApoImmune, has developed a novel immunotherapeutic approach aimed at tolerance induction to alloantigens without chronic use of general immunosuppression. This approach, terme ...

    STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government